Asymmetry Capital Management, an alternative asset management firm launched in 2013 by Scott Kay, has appointed James Yin, PhD as an analyst covering global therapeutics, based in the firm’s San Francisco headquarters.

Yin has conducted research at the National Institutes of Health (NIH) and the University of Minnesota where he participated in breakthrough research to solve the atomic structure of the Rous Sarcoma Virus Intasome. This research was published in the Journal Nature in February 2016.
 
The Asymmetry team has over 42-years combined healthcare and healthcare investing experience across market cycles and macro events.
 
CIO Scott Kay says: “James will strengthen our ability to research opportunities, long and short, in clinical-stage biotechnology, pharmaceutical companies and medical/life sciences technologies. James’ joining Asymmetry speaks to the opportunities he recognises at our firm and we are gratified to be able to attract such exemplary talent.”
 
Further Chris Zellner, COO of Asymmetry, says: “Given the investment and business opportunities we see in 2018, this is an opportune time to expand our investment team and position the firm to accommodate capital inflows. We look forward to James’ contributions to our long track record of seeking to deliver capital protection and non-correlated returns to our institutional and private investors.”